<DOC>
	<DOCNO>NCT00571519</DOCNO>
	<brief_summary>This 26-week , multicenter , randomize , double-blind , placebo active comparator-controlled , parallel-group study subject type 2 diabetes currently sub-optimally control diet exercise non-thiazolidinedione antihyperglycemic monotherapy . Pioglitazone use active comparator . The total duration subject 's participation approximately 30 week , include 2-week placebo lead-in period , 26-week double-blind treatment period , 2-week post-treatment follow-up period . Subjects complete randomize portion study per protocol may opportunity continue long-term extension study active treatment .</brief_summary>
	<brief_title>Randomized , Double-blind , Active-controlled , Study Rivoglitazone Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>type 2 diabetes HbA1c &gt; 7 % Less equal 8.5 % Cpeptide &gt; 0.5 ng/mL current monotherapy stable dose , nonthiazoleidine great equal 3 month prior screen untreated antihyperglycemic agent 2 month prior screen type 1 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>